Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) reported that on August 31, 2026, its Board Compensation Committee granted inducement stock options to two new employees for an aggregate of 31,400 shares of common stock at an exercise price of $13.07 per share under the 2025 Inducement Plan.
According to Candel Therapeutics, the options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. The awards were approved as employment inducements in line with Nasdaq Listing Rule 5635(c)(4). The 2025 Inducement Plan was adopted by the Board on December 24, 2025.
Positive
- None.
Negative
- None.
News Explained
The August 31 grants are options to purchase up to 31,400 common shares at
Market Reaction – CADL
Following this news, CADL has gained 0.54%, reflecting a mild positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $12.92.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 26 | Investor conference notice | Neutral | -2.4% | September investor conference participation was announced; shares declined 2.35% over 24 hours. |
| Aug 13 | 2Q26 earnings report | Positive | +10.6% | Quarterly results, clinical progress, and cash resources were reported; shares gained 10.63%. |
| Aug 03 | Inducement grant | Neutral | +4.4% | Options covering 30,800 shares were granted; shares gained 4.37% over 24 hours. |
| Aug 03 | Clinical data presentation | Neutral | +0.6% | Extended Phase 3 data presentation at ASTRO was announced; shares gained 0.6%. |
| Jul 29 | Investor conference notice | Neutral | -2.9% | Canaccord Growth Conference participation was announced; shares declined 2.89%. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: earnings and a prior inducement-grant announcement were followed by gains, while conference notices were followed by declines.
Key Terms
inducement stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA) and published in The Lancet Oncology. The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
